Literature DB >> 31269228

Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies.

J W Frew1, K Navrazhina1,2, A S Byrd3, A Garg4, J R Ingram5, J S Kirby6, M A Lowes1, H Naik7, V Piguet8,9, E P Prens10.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31269228      PMCID： PMC9131889          DOI： 10.1111/bjd.18309

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   11.113


× No keyword cloud information.
  8 in total

1.  Apocrine Gland-Rich Skin Has a Non-Inflammatory IL-17-Related Immune Milieu, that Turns to Inflammatory IL-17-Mediated Disease in Hidradenitis Suppurativa.

Authors:  A Jenei; Z Dajnoki; B Medgyesi; K Gáspár; G Béke; Á Kinyó; G Méhes; Z Hendrik; T Dinya; D Törőcsik; C C Zouboulis; E P Prens; T Bíró; A Szegedi; A Kapitány
Journal:  J Invest Dermatol       Date:  2018-10-31       Impact factor: 8.551

2.  'Invasive proliferative gelatinous mass' of hidradenitis suppurativa contains distinct inflammatory components.

Authors:  M Kidacki; Z Cong; A Flamm; K Helm; F W Danby; A M Nelson
Journal:  Br J Dermatol       Date:  2019-03-20       Impact factor: 9.302

3.  Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy.

Authors:  Barry Moran; Cheryl M Sweeney; Rosalind Hughes; Anna Malara; Shivashini Kirthi; Anne-Marie Tobin; Brian Kirby; Jean M Fletcher
Journal:  J Invest Dermatol       Date:  2017-06-23       Impact factor: 8.551

4.  Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa.

Authors:  G Kelly; R Hughes; T McGarry; M van den Born; K Adamzik; R Fitzgerald; C Lawlor; A M Tobin; C M Sweeney; B Kirby
Journal:  Br J Dermatol       Date:  2015-11-17       Impact factor: 9.302

5.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Authors:  Alexa B Kimball; Martin M Okun; David A Williams; Alice B Gottlieb; Kim A Papp; Christos C Zouboulis; April W Armstrong; Francisco Kerdel; Michael H Gold; Seth B Forman; Neil J Korman; Evangelos J Giamarellos-Bourboulis; Jeffrey J Crowley; Charles Lynde; Ziad Reguiai; Errol-Prospero Prens; Eihab Alwawi; Nael M Mostafa; Brett Pinsky; Murali Sundaram; Yihua Gu; Dawn M Carlson; Gregor B E Jemec
Journal:  N Engl J Med       Date:  2016-08-04       Impact factor: 91.245

Review 6.  Hidradenitis Suppurativa: Advances in Diagnosis and Treatment.

Authors:  Ditte Marie Lindhardt Saunte; Gregor Borut Ernst Jemec
Journal:  JAMA       Date:  2017-11-28       Impact factor: 56.272

7.  Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch.

Authors:  Allard R J V Vossen; Hessel H van der Zee; Lam C Tsoi; Xianying Xing; Matt Devalaraja; Johann E Gudjonsson; Errol P Prens
Journal:  Allergy       Date:  2018-12-10       Impact factor: 13.146

8.  A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa.

Authors:  John W Frew; Jason E Hawkes; James G Krueger
Journal:  F1000Res       Date:  2018-12-13
  8 in total
  9 in total

1.  Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.

Authors:  Kristina Navrazhina; John W Frew; David Grand; Samuel C Williams; Hong Hur; Juana Gonzalez; Sandra Garcet; James G Krueger
Journal:  Br J Dermatol       Date:  2022-06-02       Impact factor: 11.113

2.  The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.

Authors:  John W Frew; Kristina Navrazhina; David Grand; Mary Sullivan-Whalen; Patricia Gilleaudeau; Sandra Garcet; Jonathan Ungar; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2020-05-13       Impact factor: 11.527

3.  Doppler ultrasound-based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity.

Authors:  D Grand; J W Frew; K Navrazhina; J G Krueger
Journal:  Br J Dermatol       Date:  2020-09-06       Impact factor: 9.302

4.  Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa.

Authors:  Kristina Navrazhina; John W Frew; Patricia Gilleaudeau; Mary Sullivan-Whalen; Sandra Garcet; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2021-02-03       Impact factor: 14.290

5.  In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes.

Authors:  Kristina Navrazhina; Sandra Garcet; Juana Gonzalez; David Grand; John W Frew; James G Krueger
Journal:  J Invest Dermatol       Date:  2021-03-22       Impact factor: 7.590

6.  Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review.

Authors:  Samuel Der Sarkissian; Schapoor Hessam; Joslyn S Kirby; Michelle A Lowes; Dillon Mintoff; Haley B Naik; Hans Christian Ring; Nisha Suyien Chandran; John W Frew
Journal:  JAMA Dermatol       Date:  2022-03-01       Impact factor: 11.816

7.  The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.

Authors:  Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2021-07-30       Impact factor: 11.527

Review 8.  The Microbiome in Hidradenitis Suppurativa: A Review.

Authors:  Kirsty J L Wark; Geoffrey D Cains
Journal:  Dermatol Ther (Heidelb)       Date:  2020-11-26

9.  Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches.

Authors:  C B Ardon; C Wang; E P Prens; K R van Straalen
Journal:  Br J Dermatol       Date:  2020-09-16       Impact factor: 9.302
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.